Key Highlights

  • Park Ha Biological Technology (NASDAQ:BYAH) quoted USD 2.44, up 7.96%, in premarket trading on November 5, 2026, per the premarket quote.
  • The company filed its Annual Report for 2025 on March 2, 2026 and has filed registration statements on December 5, 2025, January 23, April 16, May 19 and June 4, 2026.
  • Published coverage of the filing cites a net loss of about USD 24 million, largely share-based compensation, against a small profit in 2024.
  • The same coverage reports a 1-for-50 reverse split in February 2026 and stores falling from 45 to 22; these items are single-source and approximate.

Annual Report and a Run of Registration Filings

Park Ha Biological Technology (NASDAQ:BYAH), a China-based skincare company that operates through Franchise stores, is quoted higher in premarket trading on November 5, 2026. The most recent major update traced in the filing record is its annual report for 2025, filed on March 2, 2026, followed by registration statements on April 16, May 19 and June 4, 2026, after earlier ones on December 5, 2025 and January 23, 2026. Registration statements are the paperwork a company files when it plans to register shares for sale, so a steady sequence of them signals continued Capital raising. The company is a foreign private issuer and does not follow the quarterly cadence of a domestic filer.

Financial Picture From Published Coverage

The figures below come from published coverage of the annual report and should be read as approximate until checked against the filing. Franchise fees account for roughly 60% of revenue, and consolidated gross Margin is reported near 94%. Product sales to non-franchisees rose 51% to about USD 536,000. Net loss was about USD 24 million, driven by about USD 24 million of share-based compensation paid to consultants, against a profit of about USD 479,000 in 2024. The same coverage describes a store network that shrank from 45 to 22 locations, a shift toward directly operated experience stores, a rise in past-due Franchisee loans to about USD 947,000, and cash of about USD 3.79 million tied to a USD 2.45 million offering in January 2026. It also reports a 1-for-50 reverse split in February 2026 that helped keep the Nasdaq listing in place. Management reported ineffective internal controls.

Thin Liquidity, Dilution and What to Watch

Several features of this profile raise Reversal risk. A small number of trades can move the price, spreads can be wide and a quoted premarket gain of 7.96% can fade once regular trading opens. A reverse split mechanically divides the share count and multiplies the price, which can leave the stock with fewer shares in public hands and more sensitivity to each sale. Share-based compensation and repeated registration filings point to dilution, because each new share issued reduces existing holders' stake in future earnings. The company also relies on third-party manufacturers that own product formulas, and its operations sit in China through a variable interest entity structure, which carries legal and regulatory uncertainty. Watch for the next filing on the 6-K form, any further offering, and an interim report covering 2026.

Where Things Stand

A 7.96% premarket gain at Park Ha Biological Technology (NASDAQ:BYAH) can hold only if buyers keep showing up in a stock where Liquidity is limited, and the filing record offers no new same-day catalyst to anchor it. The recent record shows a shrinking store base, a large non-cash compensation charge and a steady flow of registration statements. In its favor are a high gross margin, cash raised in January 2026 and a continuing listing. The next catalysts are an interim report, further financing and any update on the store network.